Akoya Biosciences, Inc. — Cyborg Score 5/10

Mixed
Life Sciences Technology / Spatial Biology / Biotechnology Research

Strategic Profile

As of July 8, 2025, Akoya Biosciences operates as a subsidiary of Quanterix Corporation, which strengthens its market position and resources. The company is positioned in the high-growth spatial biology market, targeting immuno-oncology and translational research applications with a diverse product portfolio and advanced imaging solutions.

Cyborg Score Rationale

The company generates gross profit of $47.9M but operates with negative operating income of -$46.7M on a TTM basis, indicating profitability challenges despite revenue generation. Recent acquisition by Quanterix provides strategic support, but execution and market adoption remain key metrics to monitor.

Top Insights

  • Spatial biology is an emerging market with strong biotech and pharma demand for multi-parameter tissue analysis
  • Acquisition by Quanterix for nearly $364 million validates market positioning and provides capital for growth
  • Strategic partnerships like exclusive license with NeraCare for melanoma diagnostics expand into clinical diagnostics and personalized medicine
  • Company has approximately 201 employees across 5 continents

Named Competitors

  • Ultra-sensitive Biomarker Detection — Complementary biomarker detection technology
  • Multiplexed Immunofluorescence — Competing spatial imaging solutions

Recent Developments

  • (July 2025) Akoya became a subsidiary of Quanterix Corporation
  • (2024-2025) Scott Mendel appointed as new Chairman of the Board, effective October 2, 2024
  • (Recent) Exclusive licensing agreement with NeraCare for Immunoprint test for melanoma prognostication

Open the full interactive Akoya Biosciences, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →